𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modulation of mouse RANKL gene expression by Runx2 and PKA pathway

✍ Scribed by Kiyoshi Mori; Riko Kitazawa; Takeshi Kondo; Sakan Maeda; Akira Yamaguchi; Sohei Kitazawa


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
617 KB
Volume
98
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Runx2 regulates the target genes characteristic of osteoblastic phenotypes, while exerting diverse and sometimes controversial effects on osteoblastic cells depending on their differentiation stage. Receptor activator of nuclear factor‐κB (RANK) ligand (RANKL) is a membrane bound cytokine essential for osteo(chondro)clastogenesis. During endochondral ossification, while Runx2‐positive hypertrophic chondrocytes express RANKL, the steady‐state expression of the RANKL gene in osteoblastic cells is, at later stages, kept at a relatively low level to sustain the established bone. The aim of this study was to elucidate the mechanism whereby Runx2 and the protein kinase A (PKA) pathway modulate RANKL expression, especially from the viewpoint of their functions in RANKL basic promoter activity and in chromatin structural changes in osteoblastic/stromal cells. Osteoblastic/stromal cell lines derived from normal and Runx2‐deficient mice were used to analyze endogenous RANKL gene expression by real‐time reverse transcription (RT)‐PCR, the acetylation status of the H3 and H4 histone proteins associated with the 5′‐flanking region of the RANKL gene by chromatin immunoprecipitation, and the exogenously transfected RANKL gene promoter activity both in the steady‐state and under PKA‐activated conditions. Here, we demonstrate that Runx2 suppresses steady‐state RANKL gene expression by condensing chromatin, while showing a slightly positive effect on RANKL basic promoter activity. Besides acting through the CRE‐like region (−0.96 kb) of the RANKL gene promoter, forskolin (FK) treatment transactivates the RANKL gene by antagonizing the function of Runx2, by reducing Runx2 mRNA expression and by opening the chromatin conformation far upstream (more than 40 kb) of the RANKL gene. J. Cell. Biochem. © 2006 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Modulation of mouse RANKL gene expressio
✍ Riko Kitazawa; Kiyoshi Mori; Akira Yamaguchi; Takeshi Kondo; Sohei Kitazawa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

## Abstract The expression of receptor activator of nuclear factor‐κB ligand (RANKL) is regulated by bone‐seeking hormones such as PTH and 1α,25‐dihydroxyvitamin D~3~ (1,25(OH)~2~D~3~). Runx2, a master gene for osteoblastic differentiation, also modulates osteoclastogenesis by regulating the RANKL

Modulation of gene expression by auxin
✍ Joe L. Key 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 985 KB

shock gene of Drosophilu and the E.scherichia coli heat inducible clnuK gene are homologous. Proc. Nut/. Acud.

Modulation of gene expression in the pre
✍ Gbolagade O. Babalola; Richard M. Schultz 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 765 KB

## Abstract The effect of growth factors on regulating gene expression in the preimplantation mouse embryo was examined, since results of previous experiments revealed a stimulatory effect of exogenously‐added growth factors on preimplantation development in vitro. Treatment of early cavitating bla

Modulation by bexarotene of mRNA express
✍ Fadel S. Alyaqoub; Yue Liu; Lianhui Tao; Vernon E. Steele; Ronald A. Lubet; Mich 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

## Abstract Bexarotene has demonstrated chemopreventive and therapeutic efficacy towards mouse lung tumors. Using specimens from our published study that demonstrated the efficacy of bexarotene, we report herein its ability to modulate mRNA expression of genes in both lung and lung tumors. Strain A

Modulation by budesonide of DNA methylat
✍ Michael A. Pereira; Lianhui Tao; Yue Liu; Long Li; Vernon E. Steele; Ronald A. L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 80 KB

## Abstract Biomarkers are being developed that can aid in the evaluation of cancer therapeutic and chemopreventive drugs. Two suggested biomarkers found in mouse lung tumors are DNA hypomethylation and alterations in mRNA expression of genes, such as 18S RNA, caspase 3, cyclin B2, cyclin E1, iNOS